CCRB Logo

Trial Detail

CUHK_CCRB00546

2017-02-09

Prospective

CREC 2016.416-T

N.A

Professor Regina Wing Shan SIT

N/A

Take on all the responsibilities of sponsorship jointly with the primary sponsor

Lai Yan CHOW

Room 04, 4/F, Lek Yuen Health Centre, 9 Lek Yuen Street, Shatin, N.T., Hong Kong

9540 3121

chowlyan@cuhk.edu.hk

Division of Family Medicine and Primary Health Care, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong

Hong Kong

Regina Wing Shan SIT

Room 17A, 4/F, Lek Yuen Health Centre, 9 Lek Yuen Street, Shatin, N.T., Hong Kong

2503 9053

reginasit@cuhk.edu.hk

Division of Family Medicine and Primary Health Care, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong

Hong Kong

Intra-articular and extra-articular Platelet Rich Plasma injections for knee osteoarthritis: a pilot single arm feasibility study

Intra-articular and extra-articular Platelet Rich Plasma injections for knee osteoarthritis: a pilot single arm feasibility study

先導計劃 - 研究富血小板血漿注射治療退化性膝關節炎

Hong Kong

Yes

2016-10-14

Joint CUHK-NTEC Clinical Research Ethics Committee

2016.416-T

Knee Osteoarthritis

Procedure

Intra-articular and extra-articular Platelet Rich Plasma injections

Platele Rich Plasma (PRP)

6 ml PRP plus 1 ml of 1% xylocaine (total 7 ml)

single injection

Once

N/A

N/A

N/A

N/A

N/A

1) Age ≥ 45 to ≤ 75 years old

2) Self-reported symptoms consistent with KOA per American College of Rheumatology guidelines

3) Have experienced moderate to severe knee pain for at least 3 months, defined as a score of 3 or more (0-6 ordinal response scale) on the question “What is the average level of your left/right knee pain?”

4) Failed 6 months of usual care

5) Clinical evidence of KOA according to the American College of Rheumatology guidelines

6) Radiographic evidence of KOA with Kellgren Lawerance (KL)

1) Pregnancy

2) On anticoagulation, immunosuppressive or daily opioid therapy;

3) History of collagen tissue or other autoimmune disorders;

4) Hematological diseases

5) Severe cardiovascular diseases

6) Prior or planned total knee replacement of the affected knee

7) Allergy or intolerance to acetaminophen or xylocaine

8) Body mass index (BMI) ≥ 35 kg/m2

9) Co-morbidity severe enough to prevent reliable or safe study participation

10) Subjects who cannot read or write in the Chinese Consent form

11) Interim knee joint infectious arthritis or trauma

12) Hemoglobin level < 11g/dL

13) Platelet concentration < 150,000/mm3

14) Clinical examination suggesting that the patient is not appropriate due to comorbid knee or other conditions.

45

75

Both Male and Female

Interventional

Not Applicable

Not Applicable

Open label

Single group

2

2017-02-16

12

Complete

Feasibility measurements

Test of Injection protocol, Recruitment rate,Retention rate, Adherence rate, Dropout rate, Time spend on the procedure

Baseline,16 and 26 weeks

Safety of the intervention

Reported side effects and the number of adverse events as a result of the intervention

16 and 26 weeks

Objective functional outcomes

30 second Chair test, 40 meter fast paced walk test, Timed up and go test

Baseline 16 and 26 weeks

Self-reported knee-specific pain, function and stiffness

Western Ontario McMaster University Osteoarthritis Index (WOMAC)

Baseline, 16 weeks and 26 weeks

Health-related quality of life

EuroQuol-5 questionnaire

Baseline, 16 weeks and 26 weeks

Treatment satisfaction

Qeustion:“Will you recommend the therapy to others with knee OA like yours? (yes/no)”.

at 26 weeks

Analgesics consumption

7 days recall of analgesics consumption

at 26 weeks

Acute and Constant Knee Pain Severity

The Intermittent and Constant Osteoarthritis and Pain (ICOAP)

Basline, 16 and 26 weeks

No

2017-12-01

ChiCTR-OIC-17010625

Type Document Published On  
No documents yet.
  • Page 1 of 1.